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CASE REPORT
Case report: lady with bone pains 
for 5 years—parathyroid carcinoma
Azra Rizwan1*, Abid Jamal2, Maseeh Uzzaman3 and Saira Fatima4
Abstract 
Background: Parathyroid cancer is a rare cause of primary hyperparathyroidism. It presents a diagnostic and thera-
peutic challenge that may not be recognized preoperatively, and is often not conclusively identified during the opera-
tion. We present the case of a lady with backache and hypercalcemia, but with inadequate work-up for her condition 
for several years.
Case presentation: A middle aged lady of Asian descent presented with backache. Initial work up revealed mild 
hypercalcemia, negative work up for multiple myeloma, negative sestamibi scan for parathyroid pathology. A phe-
nomenally elevated parathormone (PTH) level—2105 pg/mL (16–87 pg/mL), and rising serum calcium, 15.1 mg/dL, 
(8.6–10.5 mg/dL), ordered years later prompted a repeat sestamibi scan and ultrasonography of neck. Based on these 
investigations, a diagnosis of primary hyperparathyroidism, with high suspicion of parathyroid cancer was made. The 
patient underwent surgical tumour resection, with subsequent histopathological confirmation of diagnosis.
Conclusion: In the setting of hypercalcemia, PTH level assessment is a must. This helps to differentiate between the 
parathyroid dependant and independent causes of high serum calcium, thereby encouraging a comprehensive path-
way to the work up of the cause of hypercalcemia. The parathyroid cancer is a very rare cause of hypercalcemia, which 
needs to be considered in the differentials of primary hyperparathyroidism, particularly in the setting of high PTH levels.
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Background
Primary hyperparathyroidism affects approximately 1% 
of the world’s adult population [1]. Single parathyroid 
adenomas constitute the majority of cases (80–85%). 
Most of the remaining cases are due to hyperplasia of 
multiple parathyroid glands [1–3], with parathyroid can-
cer being a rare cause (1–2%) [1–3]. Parathyroid carci-
noma presents a diagnostic and therapeutic challenge 
as it is a rare endocrine malignancy, which may not be 
recognized preoperatively, and often is not conclusively 
identified during the operation [1].
Patients with parathyroid carcinoma usually pre-
sent with a severe form of hyperparathyroidism at the 
time of diagnosis including bone disease, renal dis-
ease, neurologic manifestations and gastrointestinal 
symptomatology, compared to the relatively asympto-
matic presentation of benign parathyroid disease [1, 4]. 
However, diagnosis is sometimes made after routine 
biochemical screening has revealed hypercalcemia in 
an asymptomatic individual who is then found to have 
raised PTH [1, 4, 5].
The etiology of parathyroid carcinoma is unclear, 
although it has been associated with neck radiation in 
sporadic cases [1]. Carcinomas have also been reported 
in familial hyperparathyroidism, such as hereditary 
hyperparathyroidism jaw tumor (HPT-JT) syndrome, 
which carries an increased risk of parathyroid cancer 
(15% vs 0.1% of sporadic parathyroid cancer) [6].
This case report describes a patient presenting with 
nonspecific bone pains, whose initial workup showed 
mild hypercalcemia, negative work up for multiple 
myeloma and a negative sestamibi scan for parathyroid 
pathology. A phenomenally elevated PTH level and ris-
ing serum calcium ordered years later prompted us to 
request for a repeat sestamibi scan and ultrasonography 
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of neck. Based on these levels & radiological tests, a diag-
nosis of primary hyperparathyroidism, with high suspi-
cion of parathyroid cancer, was made. Following this, the 
patient underwent surgical tumor resection, with subse-
quent histopathological confirmation of the diagnosis.
Case presentation
A 53  year old Pakistani lady presented to the Medicine 
clinic of a local hospital in 2004 with a history of heel 
pain and lower back pain for 5 months. In this period, the 
patient had sustained a rib fracture and left humeral frac-
ture. There was no history of diabetes, hypertension or 
any other chronic disease. She had not been on any form 
of medication, including steroids and traditional drugs 
widely available and prescribed in the region, prior to the 
onset of pain. At the time of the fractures, she had been 
placed on non steroidal anti inflammatory agents, aceta-
minophen and tramadol. There was no history of illicit 
drug use and she was a non smoker. Family history was 
unremarkable, particularly in the context of bone disease, 
and malignancy.
Initial laboratory investigations had shown a mildly ele-
vated total calcium level of 10.8 mg/dL {2.7 mmol/L}-(no 
albumin level result available from that time for correc-
tion). Parathormone levels (PTH) had not been deter-
mined. There was no vitamin d or renal function report 
available from that time. X-Ray pelvis revealed lytic 
lesions in the right iliac bone (Fig. 1). A magnetic reso-
nance imaging (MRI) of the lumbosacral spine showed 
some signal changes. The differentials based on the MRI 
were metastatic bone disease or multiple myeloma.
Serum protein electrophoresis was normal. The patient 
then got lost to follow-up. Her work up was resumed 
4 years later when her bone pains had started flaring up. 
Bone marrow examinations done back in 2007, and later 
in 2009, were negative for multiple myeloma. A bone 
scan in November 2009 showed generalized increased 
tracer uptake over the skull and both the axial and appen-
dicular skeletons- findings in favor of metabolic bone 
disease (Fig. 4a). An initial planar parathyroid sestamibi 
scan requested by a general practitioner in November 
2009 was negative for any functioning parathyroid ade-
noma in the neck or superior mediastinum. No serum 
PTH report was available from this time either. Following 
this workup, the patient was treated empirically for bone 
pains with calcium supplements, an empiric vitamin d 
injection, and intravenous zoledronic acid 5 mg (without 
prior bone mineral density assessment via DXA scan). 
This empiric treatment was instituted by an orthope-
dic surgeon whom she had been referred to. The patient 
experienced only a slight improvement in bone pains 
with this treatment and also developed nausea, vomit-
ing and anorexia. Subsequently, she sought care at the 
National Institute of Diabetes and Endocrinology, Dow 
University Health Sciences, Karachi, Pakistan.
At presentation, the patient was well oriented and of 
functional class 3 (wheel chair bound, able to walk only 
with support). Her blood pressure was 110/70 mmHg. 
Neck examination revealed no mass or lymphad-
enopathy. She had a significant proximal myopathy as 
well as curved thighs. She had shortened fingers, and 
spinal scoliosis was evident. Severe generalized bone 
tenderness was elicited. There was no focal deficit. 
Laboratory investigations at this time showed a cal-
cium level of 15.1  mg/dL{3.775  mmol/L}, (corrected 
for albumin of 3.6 mg/dL{36 g/L}); Vitamin D3 level of 
33.92  ng/mL{84.664  nmol/L}; phosphorus 2.3  mg/dL 
{0.743  mmol/L}and alkaline phosphatase of 1298  IU/L 
{21.633  µkat/L}. Her 24  h urine calcium was 155  mg/
day {3.875  mmol/day}, with urine calcium to creati-
nine ratio of 0.02. Her creatinine level was 1.3  mg/dL 
{114.92  µmol/L}(Table  1). The estimated glomerular 
Fig. 1 X-ray pelvis (punched out lytic lesions in right iliac bone)
Table 1 Laboratory work up  at  presentation to  Endocrine 
Institute—5 years after onset of backache
Laboratory investigations Normal ranges
Repeat corrected calcium 15.1 mg/dL {8.6–10.5}
Phosphorus 2.3 mg/dL {2.7–4.8}
Alkaline phosphatase 1298 IU/L {29–132}
Parathormone 2105 pg/mL {16–87}
25 OH vitamin D 33.92 ng/mL (following intramuscular 
administration of vitamin D)
{> 30}
Serum Creatinine 1.3 mg/dL {0.6–1.35}
24 h urine calcium 155 mg/day {100–300}
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filtration rate (calculated through Cockcroft-Gault 
equation) was 50 mL/min {0.835 mL/second).
Following these tests, the patient’s PTH level was 
ordered and determined to be 2105 pg/mL {2105 ng/L} 
[Table 1]. Ultrasonography of the neck showed a solid 
hypo echoic, well-circumscribed mass lesion, measur-
ing 1.8 × 1.2  cm at the lower pole of the right lobe of 
thyroid. There were no calcifications or lymphadenopa-
thy. Appearances were suggestive of parathyroid ade-
noma. Both lobes of the thyroid appeared normal. A 
repeat planar sestamibi scan, (requested from a differ-
ent institute in the city), revealed areas of tracer reten-
tion over upper and lower poles of the right lobe of 
thyroid. The intensity of retained tracer was more over 
the right inferior parathyroid gland. The findings were 
highly suggestive of hyperparathyroidism (Fig. 2).
A bone mineral density scan showed a T score of 
− 2.9 in the spine, − 3.8 in the hip and − 4.5 in the dis-
tal forearm, consistent with severe osteoporosis. The Z 
scores at the spine, hip and distal forearm were − 2.0, 
− 3.1 and − 3.6, respectively (Table 2).
Fig. 2 Parathyroid sestamibi scan (areas of tracer retention over upper and lower poles of right lobe thyroid-findings highly suggestive of primary 
hyperparathyroidism)
Table 2 Bone mineral density (BMD), T score and Z scores, 
prior to and after parathyroidectomy
◦BMD values at our institute (AKUH) for DXA done on 2.12.2009 were compared 
with the study of 11.01.2011. The comparative analysis showed statistically 
significant improvement in BMD values. The change in BMD was greater than 
the Least Significant Change (LSC) of our Department at AKUH for each region 
of interest. Therefore, it was considered significant (LSC for AKUH is: Hip: 0.030; 
Spine: − 0.034; Forearm: 0.043)
As per Institute protocol and World Health Organization (WHO) guidelines BMD 
of only the non-dominant hip (in this patient’s case, the right hip) was measured, 
(position statement of International Society for Clinical Densitometry, attached 
as Additional file 1)
Scan date 02/12/2009 (pre 
operative)
11/01/2011 
(post 
operative)
BMD hip (g/cm2)◦ 0.498 0.886
T score hip − 3.6 − 0.5
Z score hip − 3.1 0.2
BMD spine (g/cm2)◦ 0.729 0.933
T score spine − 2.9 − 1.0
Z score spine − 2.0 − 0.0
BMD forearm (g/cm2)◦ 0.333 0.402
T score forearm − 4.5 − 3.2
Z score forearm − 3.6 − 2.2
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Ultrasonography of the kidneys revealed a single renal 
stone (0.6 cm) and no neprocalcinosis.
Based on the biochemistry results of hypercalcemia, 
associated with elevated PTH levels, a diagnosis of pri-
mary hyperparathyroidism was made. Subsequent sesta-
mibi scan and neck imaging facilitated us to localize the 
abnormal parathyroid gland. The DXA scan was useful 
for evaluation of the bone mineral density. In view of the 
phenomenally high levels of parathyroid hormone, (more 
than 10 times upper limit of normal), the pre-operative 
suspicion of parathyroid cancer was high [1, 7]. The 
patient was rehydrated with intravenous fluids. Subcuta-
neous calcitonin injections at a dose of 4 units/kg every 
12 h were administered to tide her over until the surgery. 
Once her calcium levels had come down to 10.5 mg/dL 
{2.625  nmol/L}L, she was operated upon. At surgery, 
right hemithyroidectomy and inferior parathyroidectomy 
with level six lymph node resection was done. The lym-
phadenectomy was performed as there was evidence of 
enlarged lymph nodes at neck exploration. The size of 
the lesion was measured as 2.5 × 1.5 × 1 cm. Histopathol-
ogy showed features consistent with parathyroid cancer 
(Fig. 3a–d). Capsular invasion and focal vascular invasion 
were noted. However, margins of excision were tumor 
free. The excised lymph nodes did not show evidence 
of tumour infiltration. The patient was not given exter-
nal radiation therapy postoperatively. Literature review 
revealed that post operative adjuvant radiation therapy 
may only have a role in the management of patients with 
a histologically positive margin following en bloc resec-
tion, or in those with lymph node metastases [1, 4, 8].
Postoperative PTH level, performed on the second day 
of surgery, was 59 pg/mL {59 ng/L} (16–87). On the third 
postoperative day, the patient’s serum corrected calcium 
declined to 6  mg/dL {1.5  mmol/L}. This was associated 
with paresthesias around her mouth and carpo-pedal 
spasm. There were no seizures, although there was 
some confusion in terms of time and place. Intravenous 
Fig. 3 a (H&E, ×40): circumscribed parathyroid tumour composed of nests of polygonal cells with richly vascular stroma. b (H&E, ×100): tumour 
cells infiltrating adjacent soft tissue. c (H&E, ×200): high power view of tumour showing polygonal cells exhibiting nuclear atypia and scattered 
mitoses. d (H&E, ×400): tumour nests invading the blood vessel
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calcium (2  g calcium gluconate, equivalent to 180  mg 
elemental calcium, in 50  mL 5% dextrose water) was 
infused over 20  min. Re-monitoring of calcium levels 
revealed persistent hypocalcemia. A slow infusion of cal-
cium was initiated at an initial rate of 50 mL/h. This was 
prepared by adding 100  mL of 10% calcium gluconate 
(equivalent to 900  mg elemental calcium) to 1000  mL 
5% dextrose water. The infusion rate was adjusted, with 
a goal to maintain calcium levels at lower end of normal 
range. On the fifth post-operative day, the calcium level 
had risen to 9.0 mg/dL {2.25 nmol/L}. Neurologic exami-
nation was normal and she was tolerating oral diet. Oral 
calcium supplementation was initiated (Qalsan D four 
times daily-equivalent to 2 g elemental calcium per day). 
She was discharged on oral calcium and vitamin D sup-
plementation with active vitamin D, (calcitriol) 0.25  µg 
twice daily, in a stable condition.
At follow-up, her appetite and mobility had improved 
significantly, although she continued to experience bone 
pains. Corrected calcium was 9.5 mg/dL {2.375 nmol/L}. 
A repeat skeletal scintigraphy done 3  months after par-
athyroidectomy did not demonstrate a significant change 
in the lytic lesions (Fig. 4a, b). A repeat DXA scan 2 years 
down the line revealed a significant improvement in bone 
mineral density at all sites, though more so at the spine 
and hip, than at the forearm (Table 2). Thereafter, we fol-
lowed her clinically, as she was not keen to have further 
radiologic testing done. We have been monitoring her 
calcium and PTH levels on an annual basis. They have 
remained within their normal range till date (2018). She 
is now functional class 2, (no longer wheel chair bound), 
and on regular calcium and vitamin D supplements 
(patient perspective, attached as Additional file 2).
Discussion and conclusion
This case highlights several unusual features of a very 
rare disease of the parathyroid gland—parathyroid can-
cer—documented to be a causative factor in less than 
1% of cases of hyperparathyroidism [1–3]. Compared 
with patients with parathyroid adenomas, patients with 
parathyroid carcinomas are more likely to have symp-
toms, a neck mass, bone and kidney disease, marked 
hypercalcemia, very high serum parathyroid hormone 
(PTH) concentrations and, subsequently, high urinary 
calcium losses [1, 7]. In this patient, although the preop-
erative parathyroid hormone level was inexorably high 
at 2105 pg/mL (16–87), the 24 h urine calcium was not 
as high (155  mg/day) as expected in association with 
these levels of PTH [9–11], given a reasonably sufficient 
(840  mL) 24  h urine collection. The relatively low 24  h 
urine calcium could in part be explained by the reduction 
of renal function (creatinine clearance of 50  mL/min). 
The serum calcium levels were not as high as reported 
in the literature for parathyroid cancers [1, 7, 9]. The ini-
tial level was 10.8 mg/dL {2.7 mmol/L}. The highest level 
documented was 15.1  mg/dL{3.775  mmol/L}, that too 
only after she had been placed on calcium and vitamin 
d supplementation by an orthopedic surgeon, whom she 
had presented to for her bone pains. The orthopedic sur-
geon had probably been treating her as a regular case of 
primary osteoporosis, without a complete evaluation and 
consideration for the initial mildly elevated calcium of 
10.8 mg/dL {2.7 mmol/L}. The possibility exists that her 
baseline vitamin D level, unfortunately not assessed prior 
to institution of parental vitamin d, may have been low. 
This may have led to the relatively lower baseline levels 
of calcium than expected in the context of parathyroid 
carcinoma. Unmasking of primary hyperparathyroidism 
subsequent to vitamin D replacement has been reported 
in the literature [10].
Ultrasonography of our patient revealed a 1.8 × 1.2 cm 
hypo echoic, though well-circumscribed solid lesion, 
with no calcifications or lymphadenopathy, at lower 
pole of the right lobe of the thyroid. Cetani et al. in their 
review state that mass size > 3  cm, marked hypoecho-
genicity, a lobulated non homogenous pattern, calcifica-
tions and degenerative changes may raise the suspicion 
of parathyroid cancer [1, 12]. Another unusual feature 
of this patient’s presentation was that the first sestamibi 
scan was negative. The repeat scan (Fig.  2) (requested 
from a different radiologic centre) showed some tracer 
retention over the upper and lower poles of right lobe 
of thyroid, which co related with findings obtained on 
ultrasonography. The latter had revealed a mass lesion at 
the lower pole of the right lobe of the thyroid, though no 
malignant characteristics, such as calcifications, degen-
erative changes or irregular halo sign [1, 12] had been 
reported. Although both scans were planar, the nega-
tive scan had been done using a low energy general pur-
pose collimator (LEGP), while the repeat scan was done 
using a low-energy high resolution collimator (LEHR). 
The discrepancy between the results of the two sesta-
mibi scans could have been due to these different tech-
niques employed. Sestamibi scan does not distinguish 
(See figure on next page.)
Fig. 4 a Bone Scan prior to parathyroidectomy (10/11/2009): generalized increased tracer uptake over the skull, both axial and appendicular 
skeleton: findings in favour of metabolic bone disease. b Bone Scan 3 months after parathyroidectomy (18/02/2010): diffusely increased tracer 
uptake in axial and appendicular skeleton with increased bone to soft tissue tracer uptake ratio-findings consistent with metabolic bone disease. 
No appreciable change in scan pattern seen (from previous scan of 10/11/2009)
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a parathyroid adenoma from a parathyroid carcinoma 
[11]. Considering the phenomenally raised parathor-
mone levels, however, a hot nodule had been anticipated. 
The majority of cases of parathyroid cancer reported 
in the literature have described a dramatic lighting up 
of the lesion on the sestamibi scan, with a sensitivity of 
85–100%, and specificity of 100% [13]. In our case, there 
was subtle tracer retention over upper and lower poles of 
right lobe of thyroid, with intensity of retention higher 
over the inferior pole. A pin- hole collimator technique 
to obtain a magnified, higher resolution image focused 
on the neck, was not available at either Institute at that 
time. There has been a case reported in the literature of 
false negative scintigraphy in parathyroid carcinoma with 
associated brown tumours (term discussed below) [13].
From the neurologic and renal stand point the patient 
had been well preserved. There had been no manifes-
tations of altered sensorium, even at the stage when 
her serum calcium had reached a level of 15.1  mg/dL 
{3.775  mmol/L}. Ultrasonography of her kidneys had 
revealed normal sized kidneys with intact corticomed-
ullary differentiation, no nephrocalcinosis and a single 
small renal stone. In most cases of parathyroid carci-
noma, central nervous system and renal manifestations 
are apparent at the time of diagnosis [1, 4]. In the case of 
this patient, the disease, though remaining undiagnosed 
for 5  years, seems to have involved predominantly the 
skeletal system, leading to severe osteoporosis. Her short-
ened fingers on physical examination were indicative of 
pharyngeal tuft resorption. The low Z scores of ≤− 2.0 
at the spine, hip and forearm were highly suggestive of a 
secondary cause of osteoporosis. The bone mineral den-
sity at the forearm (T score − 4.5) was lower than at the 
spine (T score − 2.9) Table 2. This is in keeping with the 
fact that the parathormone has a greater impact on corti-
cal bone (distal forearm and hip) than the spine, which 
consists of cancellous bone [12]. Correspondingly, a fol-
low up dexa scan 2  years after the parathyroidectomy 
revealed a significant improvement in bone mineral den-
sity at all the sites, though a slower improvement was 
observed at the forearm (Table 2). This was likely related 
to the prolonged preoperative exposure to high levels 
of parathormone at the cortical bones of the forearm. 
The lytic lesions of the bones in primary hyperparathy-
roidism result from excess osteoclast activity leading to 
a collection of osteoclasts intertwined with fibrous tis-
sue and undermineralized woven bone. Haemosiderin 
accumulation gives rise to the brown disclouration—
hence originated the label of “brown tumours” for these 
lytic lesions [2, 12]. Correspondingly, as evident in this 
lady’s case, these lesions were originally interpreted as 
metastases or myeloma lesions radiologically. Both these 
conditions, though important differentials to consider, 
result in PTH-independent hypercalcemia, versus the 
PTH- dependant hypercalcemia ensuing from primary 
hyperparathyroidism.
Long-standing hypercalcemia resulting from autono-
mous parathormone production leads to suppression of 
the remaining parathyroid glands. Following parathyroid-
ectomy, recovery of function has been variable, ranging 
from hours to a couple of weeks. In many cases, oral cal-
cium supplementation alone adequately restores calcium 
levels. In some situations, as was the case in our patient, 
more severe hypocalcemia ensues, requiring intrave-
nous calcium supplementation. As a result of PTH sup-
pression, the 1-alfa hydroxylation of vitamin D, at the 
renal tubular level, is concurrently reduced. This neces-
sitates supplementation with the active form of vitamin 
d. This condition has been described as the “hungry bone 
syndrome”, usually found to occur 3–5  days following 
parathyroidectomy. The reason for its development is 
thought to be due to significant increases in osteoblastic 
function, bone formation and deposition of calcium and 
phosphorus in previously deprived bones [2, 14, 15]. Our 
patient had a long-standing history of primary hyperpar-
athyroidism, phenomenally elevated PTH levels, marked 
hypercalcemia and elevated alkaline phosphatase levels 
(indicating high bone resorption). She also had radiologic 
signs of osteitis fibrosa cystica (Fig.  1). These hallmarks 
very likely led to development of the typical hungry 
bone syndrome in this case. Concomitant with her long-
standing history of hyperparathyroidism, the lytic lesions 
on her follow-up bone scintigraphy, done 3 months fol-
lowing parathyroidectomy, did not show any significant 
improvement.
A number of important lessons can be learned from 
this case. In the setting of bone pains and hypercalce-
mia, the parathormone level, along with a vitamin D 
assessment and renal function tests, should have been 
checked when the patient had first presented to the 
general practitioner back in 2004. This would have dif-
ferentiated between parathyroid-dependant and par-
athyroid-independent hypercalcemia, and may have 
avoided an exhaustive work up for multiple myeloma. 
The patient had previously undergone bone marrow 
examinations on two occasions, both showing a nor-
mal result. The physicians may have been misguided 
by the only two differentials suggested on the MRI 
Lumbosacral spine report: “Multiple Myeloma versus 
metastasis.” In both these conditions, parathyroid levels 
are suppressed in the setting of hypercalcemia. Unfor-
tunately, the parathormone level and relevant testing, 
including vitamin D and renal function tests, were only 
requested 5 years down the line when the patient first 
presented to the Endocrinologist. This led to an unac-
ceptable delay in the diagnosis. It is unclear why the 
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first sestamibi scan was requested, without a prior para-
thyroid hormone level assessment, at the time when the 
patient was following up elsewhere for her condition.
In the setting of hypercalcemia, parathyroid hormone 
level assessment is a must, to differentiate between the 
parathyroid dependant and independent causes of high 
serum calcium, thereby encouraging a comprehensive 
pathway to the work-up of the cause of the hypercal-
cemia. The Parathyroid carcinoma is a very rare cause 
of hypercalcemia that can present in several ways and 
which needs to be considered in the differentials of pri-
mary hyperparathyroidism, particularly in the setting 
of high parathyroid hormone levels.
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